Long-term follow-up showed pTVG-HP nearly doubled median OS compared with placebo in biochemically recurrent prostate cancer.
|Videos|May 18, 2011
Dr. Markman Discusses the Swedish PSA Screening
Author(s)Maurie Markman, MD
Dr. Markman Discusses the Swedish PSA Screening
Advertisement
Maurie Markman, MD the National Director for Medical Oncology for the Cancer Treatment Centers of America Discusses the Swedish PSA Screening Study
Advertisement
Related to this article
The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
No efficacy benefit was found in adding SBRT to dual checkpoint blockade, though a subset of patients responded to nivolumab plus ipilimumab.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Rusfertide for Polycythemia Vera
2
DAWN-303 Trial Set to Advance INCB161734 in First-Line KRAS G12D–Mutated Metastatic Pancreatic Cancer
3
The OncFive: Top Oncology Articles for the Week of 8/23
4
FDA Grants Fast Track Designation to Varsetatug Masetecan for Relapsed/Refractory Metastatic Colorectal Cancer
5